Effect of timolol on autonomic neural discharge associated with ouabain-induced arrhythmia

European Journal of Pharmacology
C M Lathers


The purpose of this study was to determine the effect of the beta-blocking agent timolol on postganglionic cardiac and preganglionic splanchnic sympathetic and vagal neural discharge, ouabain-induced arrhythmia, heart rate and mean arterial blood pressure. Cats were anesthetized with alpha-chloralose, given atropine, and pretreated with timolol (5 mg/kg, i.v. infused at a rate of 0.5 mg/kg/min for 10 min). Bolus injections of ouabain (25 microgram/kg, i.v.) were given every 15 min until the animals died; the first injection was given 15 min after the end of the timolol infusion. When compared with cats (n = 13) receiving only ouabain, timolol (n = 11 cats) increased the time to ouabain-induced arrhythmia and death from 23 +/- 3 to 48 +/- 7 and 46 +/- 3 to 76 +/- 9 min, respectively (p less than 0.05). Both heat rate and mean arterial blood pressure had decreased from 137 +/- 4 to 104 +/- 6 beats/min and 133 +/- 6 to 103 +/- 7 mm Hg, respectively (P less than 0.05); ouabain did not reverse the decreases. Neural activity monitored from the vagus and from the postganglionic cardiac and preganglionic splanchnic sympathetic nerves was not significantly altered by the infusion of timolol. The administration of ouabain after timolol d...Continue Reading


Sep 1, 1987·Electroencephalography and Clinical Neurophysiology·C M LathersF L Weiner
Jul 1, 1989·Epilepsy Research·C M LathersB D Goldman
Feb 8, 2002·Journal of Clinical Pharmacology·C M Lathers, P L Schraeder
Jan 1, 1988·Reviews in Clinical & Basic Pharmacology·C M LathersH Klions
May 2, 2009·Epilepsy & Behavior : E&B·C M Lathers
Apr 1, 1988·Journal of Clinical Pharmacology·C M LathersN Tumer
Oct 1, 1985·Annals of Emergency Medicine·W H Spivey, C M Lathers
Oct 1, 1985·Journal of Clinical Pharmacology·C M LathersH A Klions
May 1, 1987·Journal of Clinical Pharmacology·C M Lathers, P L Schraeder
Aug 1, 1987·Journal of Clinical Pharmacology·C M Lathers, W H Spivey
Jul 1, 1989·Journal of Clinical Pharmacology·C M LathersM W Bungo
Jul 1, 1988·Journal of Clinical Pharmacology·C M LathersI Agarwal


Feb 1, 1976·European Journal of Pharmacology·P MouilléE Gauter
Feb 21, 1977·European Journal of Pharmacology·A M LeferG H Osman
Jun 1, 1978·Proceedings of the Society for Experimental Biology and Medicine·R J LeeM E Goldberg
Jan 15, 1978·European Journal of Pharmacology·P JaillonG Cheymol
Jan 1, 1976·Cardiology·R A GillisD L Pearle
May 27, 1967·Nature·J RobertsF G Standaert
May 1, 1973·British Heart Journal·P A MajidS H Taylor
Apr 1, 1974·Proceedings of the Society for Experimental Biology and Medicine·A G ProakisG R Spratto
Mar 1, 1968·Circulation Research·W C RandallM P Kaye
Mar 1, 1968·Circulation·E D FrohlichI H Page
Aug 1, 1968·European Journal of Pharmacology·C Raper, J Wale
Jun 1, 1969·British Journal of Pharmacology·A N DohadwallaE M Vaughan Williams
Mar 29, 1969·The Veterinary Record·R H Johnson
Jul 1, 1966·Canadian Journal of Physiology and Pharmacology·B R LucchesiN L Brown
Nov 1, 1967·Circulation Research·M SzentivanyiW C Randall
Dec 1, 1956·British Journal of Pharmacology and Chemotherapy·W C HOLLAND, H J SCHUMANN
Dec 1, 1958·British Journal of Pharmacology and Chemotherapy·N R EADE, D R WOOD
Jan 1, 1964·Circulation Research·J HAN, G K MOE
Feb 1, 1965·The Journal of Pharmacology and Experimental Therapeutics·P SOMANI, B K LUM

Related Concepts

Depression, Chemical
Diastolic Blood Pressure
Anti-Arrhythmia Agents
Antiarrhythmic [EPC]
Atropinum, atropine
Vagus Nerve Structure

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.